Introduction
Breast cancer is a complex disease caused by the uncontrolled growth of abnormal cells in the breast tissue, but it is crucial to recognize that it is not a single illness. Instead, it is a diverse group of diseases with numerous subtypes, each originating from different cells and driven by unique biological mechanisms that dictate their behavior, such as growth speed and response to hormones. Consequently, modern oncology care focuses on classifying the specific type of breast cancer through molecular testing, which is the most critical step in determining a patient's prognosis and creating a personalized treatment plan with targeted therapies, moving far beyond a one-size-fits-all approach.
Non-Invasive (In Situ) Breast Cancer: The Earliest Stages
The term "in situ" is Latin for "in the original place". In the context of breast cancer, it signifies the earliest possible stage, where abnormal cells are confined to the structure where they originated—either a milk duct or a lobule—and have not broken through the basement membrane to invade the surrounding breast tissue. This distinction is critical because non-invasive cancers have not yet developed the ability to spread to lymph nodes or other parts of the body. The two main forms of in situ carcinoma are Ductal Carcinoma In Situ (DCIS) and Lobular Carcinoma In Situ (LCIS), and their clinical implications are very different.
- Ductal Carcinoma In Situ (DCIS): This condition is considered Stage 0, non-invasive breast cancer. In DCIS, abnormal cells are found exclusively within the lining of the breast's milk ducts. It is a common finding, accounting for approximately 20-25% of all new breast cancer diagnoses in the United States, largely due to the effectiveness of screening mammography. While DCIS is not life-threatening in its current state, it is considered a direct precursor to invasive cancer. If left untreated, the abnormal cells can eventually break through the duct wall and become invasive ductal carcinoma (IDC). Studies estimate that this progression may occur in 20-50% of untreated cases. Because of this risk, DCIS is actively treated, typically with surgery (lumpectomy or mastectomy) often followed by radiation therapy. With treatment, the prognosis is excellent, and nearly all individuals are cured.
- Lobular Carcinoma In Situ (LCIS): It is essential to understand that LCIS is not cancer. Instead, it is classified as a "lobular neoplasia"—a growth of abnormal cells contained within the milk-producing glands (lobules).18 The primary significance of an LCIS diagnosis is its role as a powerful risk marker. It indicates that an individual has a substantially higher risk of developing invasive breast cancer later in life, and this increased risk applies to both breasts, not just the one where LCIS was found. The relative risk is estimated to be about 9 to 10 times that of the general population. Consequently, the management of LCIS differs fundamentally from that of DCIS. Rather than aggressive treatment, the standard approach is typically active surveillance, which involves more frequent clinical exams and imaging, and sometimes risk-reducing medications (chemoprevention) to lower the chance of a future cancer developing.
The divergent management of DCIS and LCIS illustrates a crucial advancement in oncology: the move toward a nuanced, risk-stratified approach to care. By distinguishing between a true precursor lesion that requires treatment to prevent progression (DCIS) and an indicator of future risk that calls for surveillance (LCIS), clinicians can avoid the potential harm of over-treating a condition that is not cancer itself. This careful classification helps to mitigate patient anxiety and ensures that the intensity of the intervention matches the true nature of the diagnosis.
The Most Common Diagnoses
When breast cancer is described as "invasive" or "infiltrating," it means the cancer cells have breached the walls of their original location (the ducts or lobules) and have begun to grow into the surrounding breast stroma, which is the fatty and connective tissue of the breast. This is a critical turning point because, once in the stroma, cancer cells can gain access to the lymphatic system and bloodstream. This access gives them the potential to travel to lymph nodes and metastasize to distant parts of the body.7 The vast majority of breast cancers diagnosed are invasive.
- Invasive Ductal Carcinoma (IDC): This is by far the most common type of breast cancer, responsible for approximately 70-80% of all invasive diagnoses. As its name suggests, IDC begins in the cells lining a milk duct. The cancer then breaks through the duct wall and invades the adjacent breast tissue. Clinically, IDC often presents as a firm or hard lump with irregular edges that can be felt during a physical exam or is readily detected as a distinct mass on a mammogram.
- Invasive Lobular Carcinoma (ILC): The second most common type, ILC accounts for about 10-15% of invasive breast cancers. It originates in the milk-producing glands, or lobules, before spreading into the nearby breast tissue. ILC is distinguished by a key biological feature: its cells typically lack E-cadherin, a cell-adhesion protein that acts like glue to hold cells together. This absence causes ILC cells to grow in a diffuse, disconnected pattern, often forming single-file lines or sheets rather than a cohesive, solid lump.
This fundamental cellular difference between IDC and ILC has a cascade of clinically important consequences. The diffuse growth pattern of ILC makes it notoriously difficult to detect. It may not form a palpable lump, instead presenting as a subtle thickening, fullness, or hardening of the breast tissue. On a mammogram, it may be invisible or appear only as a subtle architectural distortion, leading to challenges in diagnosis and potential delays. Because the full extent of ILC is harder to visualize pre-operatively, surgeons often discover that the cancer is larger than imaging suggested, which can necessitate more extensive surgery. Furthermore, the non-cohesive nature of ILC cells influences where they spread; while they can metastasize to common sites like bone and lungs, they have a unique propensity to spread to unusual locations such as the gastrointestinal tract, the lining of the abdomen (peritoneum), and the ovaries.
Special and Aggressive Breast Cancer Types
Beyond the common classifications of IDC and ILC, breast cancers are further subtyped based on their molecular profile. This involves testing the cancer cells for the presence or absence of three key proteins that can act as receptors: the Estrogen Receptor (ER), the Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2). This molecular signature is one of the most powerful predictors of a tumor's behavior and the single most important factor in guiding the use of targeted therapies.
- Triple-Negative Breast Cancer (TNBC): This subtype is defined by what it lacks: it tests negative for estrogen receptors, progesterone receptors, and excess HER2 protein.3 Accounting for about 10-15% of all breast cancers, TNBC is known for its aggressive behavior; it tends to grow and spread more rapidly than other types. It is disproportionately diagnosed in women under the age of 40, Black women, and individuals who carry an inherited mutation in theBRCA1 gene. The absence of the three standard receptors presents a significant treatment challenge, as TNBC does not respond to hormone therapies or drugs that target HER2. Consequently, chemotherapy has long been the primary systemic treatment, although immunotherapy has emerged as a vital new option for some patients.
- HER2-Positive Breast Cancer: These cancers are characterized by an overabundance of the HER2 protein on the cell surface, a condition caused by the cancer cells having extra copies of the HER2 gene. This subtype makes up about 15-20% of invasive breast cancers. The excess HER2 protein functions as a potent accelerator, driving rapid cell growth and making these cancers inherently aggressive.3 However, this same protein provides a clear target for treatment. The development of HER2-targeted drugs, such as trastuzumab and pertuzumab, which specifically block the HER2 protein, has revolutionized the treatment of this subtype and dramatically improved what was once a poor prognosis.
- Inflammatory Breast Cancer (IBC): IBC is a rare but extremely aggressive form of invasive ductal carcinoma, accounting for only 1-5% of cases. It is unique in its clinical presentation. IBC typically does not form a distinct lump. Instead, cancer cells invade and block the lymphatic vessels in the skin of the breast. This blockage causes the breast to become swollen, red, warm, and tender. The skin may also develop a pitted appearance, similar to an orange peel, a sign known aspeau d'orange. Because cancer cells are already in the skin, IBC is always considered at least Stage III at diagnosis. Its rapid progression requires a prompt and aggressive multimodal treatment approach, usually beginning with chemotherapy to shrink the tumor, followed by surgery and radiation therapy.
When Cancer Spreads
Metastatic breast cancer is not a specific type of breast cancer itself, but rather the most advanced stage of the disease—Stage IV. This stage is defined by the cancer having spread (metastasized) from the breast and nearby lymph nodes to distant parts of the body. Cancer cells accomplish this by breaking away from the primary tumor and traveling through the bloodstream or lymphatic system, eventually settling and forming new tumors in other organs.
The most common sites for breast cancer metastasis are the bones, lungs, liver, and brain.It is crucial to understand that even when a tumor is found in a different organ, it is still composed of breast cancer cells and is treated as such. For example, breast cancer that has spread to the bones is called metastatic breast cancer, not bone cancer.
A diagnosis of metastatic breast cancer can occur in two ways: it may be the initial diagnosis (known as de novo metastatic breast cancer), or it can be a recurrence of a previous, early-stage breast cancer, sometimes appearing months or even many years after the initial treatment was completed.
At this stage, the disease is considered widespread and is not curable, as it is impossible to surgically remove or irradiate every cancer cell in the body. This reality fundamentally reframes the goal of treatment. The focus shifts from attempting to eradicate the disease to managing it as a long-term, chronic condition. The primary objectives become slowing or stopping tumor growth, relieving symptoms caused by the tumors, and extending and preserving the patient's quality of life for as long as possible. Treatment is systemic (whole-body) and is guided by the biological characteristics of the cancer, including its hormone receptor and HER2 status. A range of therapies, including hormone therapy, chemotherapy, targeted therapy, and immunotherapy, are used to control the disease, often in sequence, as the cancer evolves over time. This approach transforms the patient's relationship with their illness from a finite battle to be won into an ongoing condition to be managed, highlighting the immense importance of palliative care and continuous research into new therapies that can help people live longer, fuller lives with metastatic disease.
How Your Cancer Type Guides Your Treatment Path
The modern treatment of breast cancer is the epitome of personalized medicine. A treatment plan is not based on a single factor but is instead a carefully constructed strategy built upon the unique pathological and biological profile of an individual's cancer.3 This process resembles assembling a puzzle, where each piece of information from the pathology report helps to reveal the full picture and dictates the next move.
The key factors that guide these critical treatment decisions include:
- Invasive vs. Non-Invasive Status: This is the first major branch in the decision tree. A non-invasive cancer like DCIS is contained and may be fully treated with local therapies such as surgery and radiation. An invasive cancer, having already breached its containment, carries a risk of systemic spread, meaning that whole-body (systemic) treatments are often necessary to eliminate any cancer cells that may have escaped.
- Hormone Receptor (HR) Status: If tests show a cancer is estrogen receptor-positive (ER+) and/or progesterone receptor-positive (PR+), it means the cancer cells have receptors that use these hormones as fuel to grow. This provides a clear therapeutic target. The treatment plan will include hormone-blocking therapies (also called endocrine therapy), such as tamoxifen or aromatase inhibitors, which work by either blocking the receptors or lowering the body's estrogen levels, effectively starving the cancer cells. These drugs are completely ineffective for hormone receptor-negative (HR-) cancers.
- HER2 Status: If a cancer is found to be HER2-positive, its cells are producing an excess of the growth-promoting HER2 protein. This protein is the target for a powerful class of drugs known as anti-HER2 therapies. These drugs specifically seek out and block the HER2 protein or deliver toxins directly to HER2-positive cells, halting their aggressive growth. For HER2-negative cancers, these drugs have no target and are therefore not used.
- Triple-Negative Status: For a TNBC diagnosis, the pathology report shows the cancer is ER-negative, PR-negative, and HER2-negative. This means that the "keys" of hormone therapy and anti-HER2 drugs will not work because the corresponding "locks" are not present on the cancer cells. Therefore, the treatment strategy must rely on other methods, primarily chemotherapy, which kills rapidly dividing cells more generally, and in some cases, immunotherapy, which helps the body's own immune system attack the cancer.
This "lock-and-key" approach makes the logic behind a treatment plan transparent. For a patient with a Stage II, ER-positive, HER2-negative IDC, the plan logically follows: surgery and radiation for local control (due to its stage and invasive nature), hormone therapy because the ER "lock" is present, and no HER2 therapy because the HER2 "lock" is absent. The grade and stage then help determine whether the potential benefit of adding chemotherapy outweighs the risks. This personalized strategy ensures that each individual receives the therapies most likely to be effective against their specific disease while being spared the toxicity of those that will not.
Conclusion
Understanding the specific type of breast cancer is paramount for anyone navigating this diagnosis. This detailed knowledge empowers patients and their healthcare teams to make informed decisions, leading to personalized treatments tailored to the cancer’s unique biology. Continuous advancements in research for each distinct type offer ever-improving outcomes, providing a strong foundation for hope and the promise of more effective, targeted care.
Frequently Asked Questions
Q: What is the most common type of breast cancer?
A: The most common type is Invasive Ductal Carcinoma (IDC), accounting for about 80% of all invasive breast cancers. It begins in the milk ducts and spreads into surrounding breast tissue, often forming a distinct lump.
Q: How do triple-negative cancers differ from others?
A: Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, making it unresponsive to hormone or anti-HER2 therapies. It is often more aggressive, grows faster than other types, and relies on chemotherapy as its main systemic treatment.
Q: Can non-invasive breast cancer progress to invasive?
A: Yes, Ductal Carcinoma In Situ (DCIS), a Stage 0 cancer, can become invasive if left untreated, which is why treatment is recommended. In contrast, Lobular Carcinoma In Situ (LCIS) is not cancer but a condition that increases the future risk of developing invasive cancer.
Works cited
- Types of Breast Cancer - National Breast Cancer Foundation, fecha de acceso: julio 25, 2025, https://www.nationalbreastcancer.org/types-of-breast-cancer/
- Triple-negative breast cancer: 7 things you should know, fecha de acceso: julio 25, 2025, https://www.mdanderson.org/cancerwise/triple-negative-breast-cancer-5-things-you-should-know.h00-158986656.html
- Subtypes of Breast Cancer - NCBI, fecha de acceso: julio 25, 2025, https://www.ncbi.nlm.nih.gov/books/NBK583808/
- Breast cancer - Diagnosis and treatment - Mayo Clinic, fecha de acceso: julio 25, 2025, https://www.mayoclinic.org/diseases-conditions/breast-cancer/diagnosis-treatment/drc-20352475
- Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications - PubMed Central, fecha de acceso: julio 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4952020/
- Prognosis | Breast Cancer Now, fecha de acceso: julio 25, 2025, https://breastcancernow.org/about-breast-cancer/diagnosis/primary-breast-cancer-prognosis
- Types of Breast Cancer - Johns Hopkins Pathology, fecha de acceso: julio 25, 2025, https://pathology.jhu.edu/breast/types-of-breast-cancer/
- Ductal Carcinoma In Situ (DCIS) - National Breast Cancer Foundation, fecha de acceso: julio 25, 2025, https://www.nationalbreastcancer.org/dcis/
- Stage 0 Breast Cancer - Symptoms, Treatment & Survival Rate, fecha de acceso: julio 25, 2025, https://www.nationalbreastcancer.org/breast-cancer-stage-0/
- Noninvasive breast cancer (DCIS or LCIS) | Sylvester Comprehensive Cancer Center | University of Miami Health System, fecha de acceso: julio 25, 2025, https://umiamihealth.org/sylvester-comprehensive-cancer-center/treatments-and-services/breast-cancer/noninvasive-breast-cancer-(dcis-or-lcis)-
- Types of breast cancer, fecha de acceso: julio 25, 2025, https://breastcancernow.org/about-breast-cancer/diagnosis/types-of-breast-cancer
- Types of Breast Cancer, fecha de acceso: julio 25, 2025, https://www.arizonabloodandcancerspecialists.com/types-of-breast-cancer/
- Pre-invasive - Breast Cancer Foundation NZ, fecha de acceso: julio 25, 2025, https://www.breastcancerfoundation.org.nz/breast-cancer/types-of-breast-cancer/pre-invasive
- Treatment of Ductal Carcinoma in Situ (DCIS) - American Cancer Society, fecha de acceso: julio 25, 2025, https://www.cancer.org/cancer/types/breast-cancer/treatment/treatment-of-breast-cancer-by-stage/treatment-of-ductal-carcinoma-in-situ-dcis.html
- Ductal Carcinoma In Situ: The Weight of the Word “Cancer”, fecha de acceso: julio 25, 2025, https://www.aacr.org/blog/2022/10/12/ductal-carcinoma-in-situ-the-weight-of-the-word-cancer/
- Ductal Carcinoma In Situ (DCIS) – What You Need To Know - Susan G. Komen®, fecha de acceso: julio 25, 2025, https://www.komen.org/blog/ductal-carcinoma-in-situ-dcis-what-you-need-to-know/
- Ductal Carcinoma in Situ (DCIS) - Johns Hopkins Medicine, fecha de acceso: julio 25, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/breast-cancer/ductal-carcinoma-in-situ
- Non-Invasive Breast Cancers | ACS - The American College of Surgeons, fecha de acceso: julio 25, 2025, https://www.facs.org/for-patients/the-day-of-your-surgery/breast-cancer-surgery/breast-cancer-types/noninvasive-breast-cancers/
- Types of breast cancer and related breast conditions - Cancer Research UK, fecha de acceso: julio 25, 2025, https://www.cancerresearchuk.org/about-cancer/breast-cancer/types
- Lobular carcinoma in situ (LCIS) - Symptoms & causes - Mayo Clinic, fecha de acceso: julio 25, 2025, https://www.mayoclinic.org/diseases-conditions/lobular-carcinoma-in-situ/symptoms-causes/syc-20374529
- Lobular Carcinoma in Situ - Johns Hopkins Medicine, fecha de acceso: julio 25, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/breast-cancer/lobular-carcinoma-in-situ
- Lobular Carcinoma in Situ (LCIS) - Cedars-Sinai, fecha de acceso: julio 25, 2025, https://www.cedars-sinai.org/health-library/diseases-and-conditions/l/lobular-carcinoma-in-situ-lcis.html
- Non-invasive breast carcinoma - PubMed, fecha de acceso: julio 25, 2025, https://pubmed.ncbi.nlm.nih.gov/1325215/
- Lobular Carcinoma in Situ - PMC - PubMed Central, fecha de acceso: julio 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5841603/
- Types of Breast Cancer | About Breast Cancer | American Cancer ..., fecha de acceso: julio 25, 2025, https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer.html
- Types of Breast Cancer, fecha de acceso: julio 25, 2025, https://www.saintjohnscancer.org/breast/breast-cancer/types-of-breast-cancer/
- www.cdc.gov, fecha de acceso: julio 25, 2025, https://www.cdc.gov/breast-cancer/about/index.html#:~:text=Invasive%20ductal%20carcinoma%20(IDC)%20is,other%20parts%20of%20the%20breast.
- Invasive Ductal Carcinoma (IDC) | Johns Hopkins Medicine, fecha de acceso: julio 25, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/breast-cancer/invasive-ductal-carcinoma-idc
- Breast Cancer Basics - CDC, fecha de acceso: julio 25, 2025, https://www.cdc.gov/breast-cancer/about/index.html
- Invasive Breast Cancer (IDC/ILC) - American Cancer Society, fecha de acceso: julio 25, 2025, https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/invasive-breast-cancer.html
- Breast cancer types: What your type means - Mayo Clinic, fecha de acceso: julio 25, 2025, https://www.mayoclinic.org/diseases-conditions/breast-cancer/in-depth/breast-cancer/art-20045654
- 7 early signs of breast cancer and why knowledge is power in this disease, fecha de acceso: julio 25, 2025, https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/breast-cancer-symptoms-7-early-signs-of-breast-cancer-and-why-knowledge-is-power-in-this-disease/articleshow/122586900.cms
- Invasive Lobular Carcinoma (ILC) - Cancer Treatment Centers of America, fecha de acceso: julio 25, 2025, https://www.cancercenter.com/cancer-types/breast-cancer/types/common-breast-cancer-types/invasive-lobular-carcinoma
- Cancer Stat Facts: Invasive Lobular Carcinoma - SEER, fecha de acceso: julio 25, 2025, https://seer.cancer.gov/statfacts/html/ilc.html
- 8 insights on lobular breast cancer, fecha de acceso: julio 25, 2025, https://www.mdanderson.org/cancerwise/What-is-invasive-lobular-carcinoma-8-insights-on-lobular-breast-cancer.h00-159539745.html
- Different Gene Expression Patterns in Invasive Lobular and Ductal Carcinomas of the Breast, fecha de acceso: julio 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC420079/
- Breast Cancer Hormone Receptor Status - American Cancer Society, fecha de acceso: julio 25, 2025, https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-hormone-receptor-status.html
- Hormone Receptor Positive (HR+) Breast Cancer - Penn Medicine, fecha de acceso: julio 25, 2025, https://www.pennmedicine.org/conditions/hr-positive-breast-cancer
- Triple-negative Breast Cancer | Details, Diagnosis, and Signs, fecha de acceso: julio 25, 2025, https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html
- www.cancer.org, fecha de acceso: julio 25, 2025, https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/triple-negative.html#:~:text=Triple%2Dnegative%20breast%20cancer%20(TNBC,a%20worse%20prognosis%20(outlook).
- Understanding triple-negative breast cancer and its treatment, fecha de acceso: julio 25, 2025, https://cancerblog.mayoclinic.org/2024/01/03/understanding-triple-negative-breast-cancer-and-its-treatment/
- What Causes Triple Negative Breast Cancer | Moffitt, fecha de acceso: julio 25, 2025, https://www.moffitt.org/cancers/triple-negative-breast-cancer/diagnosis/causes/
- www.mayoclinic.org, fecha de acceso: julio 25, 2025, https://www.mayoclinic.org/diseases-conditions/breast-cancer/expert-answers/breast-cancer/faq-20058066#:~:text=HER2%2Dpositive%20breast%20cancer%20is,that%20makes%20the%20HER2%20protein.
- What is HER2 Status? - Breast Cancer, fecha de acceso: julio 25, 2025, https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html
- HER2 positive breast cancer: What it is, diagnosis and treatment, fecha de acceso: julio 25, 2025, https://www.mdanderson.org/cancerwise/her2-positive-breast-cancer--what-it-is--diagnosis-and-treatment.h00-159542112.html
- HER2-positive breast cancer: What is it? - Mayo Clinic, fecha de acceso: julio 25, 2025, https://www.mayoclinic.org/diseases-conditions/breast-cancer/expert-answers/breast-cancer/faq-20058066
- Inflammatory Breast Cancer | Details, Diagnosis, and Signs, fecha de acceso: julio 25, 2025, https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/inflammatory-breast-cancer.html
- Inflammatory Breast Cancer | Diagnosis and Treatment | University of Michigan Rogel Cancer Center, fecha de acceso: julio 25, 2025, https://www.rogelcancercenter.org/breast-cancer/inflammatory-breast-cancer
- What is Inflammatory Breast Cancer? Symptoms, Risk Factors & Treatments, fecha de acceso: julio 25, 2025, https://www.mdanderson.org/cancer-types/inflammatory-breast-cancer.html
- Metastatic (Stage 4) Breast Cancer | Penn Medicine, fecha de acceso: julio 25, 2025, https://www.pennmedicine.org/conditions/metastatic-breast-cancer
- Metastatic breast cancer, fecha de acceso: julio 25, 2025, https://en.wikipedia.org/wiki/Metastatic_breast_cancer
- www.hopkinsmedicine.org, fecha de acceso: julio 25, 2025, https://www.hopkinsmedicine.org/health/conditions-and-diseases/breast-cancer/metastatic-breast-cancer#:~:text=Metastatic%20breast%20cancer%20is%20cancer,is%20stage%20IV%20breast%20cancer.
- Overview: Metastatic breast cancer - InformedHealth.org - NCBI Bookshelf, fecha de acceso: julio 25, 2025, https://www.ncbi.nlm.nih.gov/books/NBK361001/
- A Look at Common and Uncommon Types of Breast Cancer | Northwestern Medicine, fecha de acceso: julio 25, 2025, https://www.nm.org/healthbeat/healthy-tips/the-truth-about-breast-cancer
- Treatment of Breast Cancer Stages I-III, fecha de acceso: julio 25, 2025, https://www.cancer.org/cancer/types/breast-cancer/treatment/treatment-of-breast-cancer-by-stage/treatment-of-breast-cancer-stages-i-iii.html
- Hormone Receptor-Positive Breast Cancer: Why Your HR Status Matters for Treatment Decisions - Susan G. Komen®, fecha de acceso: julio 25, 2025, https://www.komen.org/blog/know-more-hr-positive-breast-cancer/
- Hormone Receptor Status In Breast Cancer, fecha de acceso: julio 25, 2025, https://www.oregoncancer.com/breast-cancer/hormone-receptor-status-in-breast-cancer
- Breast Cancer Treatment - NCI, fecha de acceso: julio 25, 2025, https://www.cancer.gov/types/breast/patient/breast-treatment-pdq
